D-0529-2023 Class III Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-0529-2023 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Mar 29, 2023 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Above the specification limits yielded for related substance norepinephrine sulfonic acid impurity during routine product monitoring. The recall status is terminated (terminated Oct 31, 2023). Affected quantity: 16,450 vials.

Recall details

Product Type
Drugs
Report Date
Apr 19, 2023
Initiation Date
Mar 29, 2023
Termination Date
Oct 31, 2023
Product Quantity
16,450 vials

Product description

Norepinephrine Bitartrate Injection, USP, 4 mg/4 mL* (1 mg/mL), 4 mL Single-dose Fliptop Vial (NDC 47335-615-40); packaged in 10 x 4 mL Single-dose Fliptop Vials per carton (NDC 47335-615-44); Rx only, Manufactured by: Gland Pharma Limited, Hyderabad-502307 India; Distributed by: Sun Phamaceutical Industries, Inc., Cranbury, NJ 08512.

Reason for recall

Failed Impurities/Degradation Specifications: Above the specification limits yielded for related substance norepinephrine sulfonic acid impurity during routine product monitoring.

Distribution pattern

Nationwide in the USA

Code information

Lot Number: G1510001, Exp 11/2023; G151002, Exp. 12/2023; and G151003, Exp 02/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0529-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0529-2023. Report a data issue: hello@regdatalab.com.